NCT07664891 Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma
| NCT ID | NCT07664891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Paoli-Calmettes |
| Condition | Pancreatic Adenocarcinoma Metastatic |
| Study Type | OBSERVATIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-09-11 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 64 participants in total. It began in 2025-09-11 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers. Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: 1. Age \> 18 years 2. Signed written informed consent specific to the PROMETAP study 3. Affiliation with a social security system 4. Treatment and follow-up performed at the Institut Paoli-Calmettes 5. Metastatic PDAC requiring biopsy as part of routine care (group1 and 2) 6. Prior treatment: * No previous chemotherapy for the "initial" group * No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group 7. Eligible for chemotherapy (ECOG \< 2) Non-Inclusion Criteria: 1. Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2) 2. Absence of a metastasis accessible to biopsy (group1 and 2) 3. Concurrent treatment for another active cancer 4. Pregnant or breastfeeding women 5. Patients in emergency situations 5\. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07664891 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Adenocarcinoma Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07664891 currently recruiting?
Yes, NCT07664891 is actively recruiting participants. Contact the research team at drci.up@ipc-unicancer.fr for enrollment information.
Where is the NCT07664891 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT07664891 clinical trial?
NCT07664891 is sponsored by Institut Paoli-Calmettes. The trial plans to enroll 64 participants.